Healthymity
An ecosystem for collaboration hospitals and pharmaceutical companies on AI projects

The core elements we provide:
- Health data analytics (data mining, data aggregation, data modelling, etc.)
- Artificial intelligence (AI) solutions for treatment and care (computer vision, investigation of surgical workflows, knowledge representation, learning from data).
- Annotation/labelling for video (e.g. surgical procedures) and static data (e.g. histopathology, x-rays, etc.), ensuring high quality of annotations and data preparation for machine learning (ML).
- Data anonymization, data reuse, and data security.
- Situation awareness, reasoning and decision support techniques.
- Complex analysis of AI and ML solutions for healthcare, including deep learning algorithms, recommendation systems and end-to-end decision-making (DM) systems.
Our research group proceeds a large amount of multi-modal data from electronic health records, cameras, and medical devices to develop AI-based systems to assist clinicians and staff in their medical routines.
To ensure privacy and security while training ML models, we utilize rigorous data preparation alongside with series of data protection techniques in the federated learning pipeline as data aggregation, perturbation, cleaning.
Latest News
Early stage clinical trials: Current Stage
Individual Case Safety Reports (ICSR)
Extracting ICSR specific information is one of the biggest challenges facing the industry
- ICSR involves understanding the complete text and entering into the case, the details of the adverse event, drugs, patient data, his/her history and so on
RQ:
- data sharing
- store user data
- volume growth
- privacy and security of sensitive data

The goal:
to develop a best-in-class platform that connects clinical and non-clinical data to accelerate drug discovery and treatment advancements for patients
Priorities:
- Customer engagement
- Privacy and Security
- Accuracy andEfficiency
Tools and technologies:
- Distributed ledger
technology - Federated learning
- Machine learning and AI
State-of-the Art
Tools and enterprise solutions around Federated Learning and other secure computation techniques across different verticals
Drug design startups
186 Startups Using AI in Drug Discovery
- Aggregate and synthesize information
- Understand mechanisms of disease
- Establish biomarkers
- Generate data and models
- Repurpose existing drugs
- Generate novel drug candidates
- Validate and optimize drug candidates
- Design drugs
- Design preclinical experiments
- Run preclinical experiments
- Design clinical trials
- Recruit for clinical trials
- Optimize clinical trials
- Publish data
- Analyze real world evidence
40 Pharma Companies Using AI in Drug Discovery
What we propose
Federated biomedical research and healthcare AI ecosystem
Artificial Intelligence-powered platform for drug discovery and collaboration pharmaceutical companies, hospitals andindividual users Source

Three core components


Orchestrated Customer Engagement
- Our model enables more effective customer engagement
- It can engage different stakeholders include payers, providers and
influencers, which range from national healthcare organizations to
diagnosticians, pathologists and health informatics experts. - It also includes bodies like clinical commissioning groups, specialized
commissioning and specialist trusts; as well as Cancer Alliances and
primary care hospitals.

Support full-stack privacy and security
- We use federated learning and homomorphic encryption to keep sensitive
data private. - Ecosystem based on a distributed edge computing infrastructure.
- Train an algorithm across multiple decentralized edge devices or servers
holding local data samples, without exchanging their data samples. - These enable to reduce cloud infrastructure overheads and optimize all
available resources for efficient and economical scaling

Acceleration meaningful healthcare outcomes
- drug-discovery algorithms on each-other’s data
- algorithms might be trained on a pharma company’s data but data
itself wouldn’t be shared with collaborators instead, the models from
each dataset are shared and averaged together in the central model - model development, training, and evaluation with no direct access to
or labelling of raw data, with communication cost as a limiting factor
Why it works
HEADQUARTERS
Sunderland Software Centre
Tavistock Pl, Sunderland SR1 1PB,
United Kingdom
Tavistock Pl, Sunderland SR1 1PB,
United Kingdom
R&D
6 Strokacha str. Kyiv, Ukraine 03148
+380 44 596 41 51